B

Bambusa Therapeutics BBTX

$16.09

−3.94%

Nov 13

1W

1M

Activities

Bispecific antibodies

Dermatology drugs

Respiratory drugs

Autoimmune disease drugs

Sign in to see the AI's note on Bambusa Therapeutics, Inc. Common stock.

Posts

Bambusa Therapeutics

1w ago · 5% stake

RA Capital declares 14.6% of Bambusa Therapeutics after its IPO

RA Capital Management holds 14.6% of newly listed Bambusa Therapeutics and says it is investing, with no plan to change control.

Bambusa Therapeutics

1w ago · Insider buying

RA Capital funds buy $46.6 million of newly listed Bambusa shares

Two RA Capital funds bought about $46.6 million of Bambusa Therapeutics shares on October 30 and November 2, in a filing made public on November 3.

See all posts →

About Bambusa Therapeutics, Inc. Common stock

Bambusa Therapeutics is a clinical-stage biotech developing long-acting bispecific antibodies (single drugs that block two disease targets at once) for immune and inflammatory diseases. Its lead drugs target eczema and chronic hives (BBT001) and COPD and nasal polyps (BBT002), both licensed from BioNTech's Zhuhai unit. It has no products on sale and no revenue, and funds its trials with money raised from investors, most recently its October 2026 IPO.